Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Patients With Neovascular Age-Related Macular Degeneration Studies in Japan and the United States

Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Patients With Neovascular Age-Related Macular Degeneration : Studies in Japan and the United States

© 2019 Kunimoto, Ohji, Maturi, et al.

Bibliographische Detailangaben
Veröffentlicht in:Ophthalmic surgery, lasers & imaging retina. - 2013. - 50(2019), 2 vom: 01. Feb., Seite e10-e22
1. Verfasser: Kunimoto, Derek (VerfasserIn)
Weitere Verfasser: Ohji, Masahito, Maturi, Raj K, Sekiryu, Tetsuju, Wang, Ying, Pan, Grace, Li, Xiao-Yan, Schneider, Susan, BAMBOO and CYPRESS Study Groups
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2019
Zugriff auf das übergeordnete Werk:Ophthalmic surgery, lasers & imaging retina
Schlagworte:Clinical Trial, Phase II Journal Article Multicenter Study Randomized Controlled Trial Angiogenesis Inhibitors Recombinant Fusion Proteins Vascular Endothelial Growth Factor A abicipar pegol M55Q728KNA Ranibizumab ZL1R02VT79
Online verfügbar Volltext